Dr. Iliyan D. Iliev, an associate professor of immunology and microbiology in the Division of Gastroenterology and Hepatology and a member of the Jill Roberts Institute for Research in Inflammatory Bowel Disease at Weill Cornell Medicine, has been awarded a five-year, $1.25 million CRI Lloyd J. Old STAR (Scientists Taking Risks) Program grant from Cancer Research Institute (CRI).
The incidence of inflammatory bowel disease (IBD)-;an intractable disease characterized by chronic inflammation of the gastrointestinal (GI) tract-;has increased significantly in Japan.
A protein called Zbtb46, expressed by specialized immune cells, has a major role in protecting the gastrointestinal tract from excessive inflammation, according to a study from researchers at Weill Cornell Medicine.
Researchers at Saint Louis University's School of Medicine, in collaboration with Arrowhead Pharmaceuticals and Takeda Pharmaceuticals, report the first effective drug to treat a rare, genetic liver disease that formerly could only be treated with a liver transplant.
It is important to know whether patients have non-alcoholic fatty liver disease (NAFLD) or alcohol-related liver disease (ALD), as this distinction plays a key role in treatment and prognosis but cannot be reliably determined by established diagnostic means.